Search

Your search keyword '"Wedemeyer H."' showing total 2,206 results

Search Constraints

Start Over You searched for: Author "Wedemeyer H." Remove constraint Author: "Wedemeyer H."
2,206 results on '"Wedemeyer H."'

Search Results

2. Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients

3. Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure

8. Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1–3 Infections

11. A global research priority agenda to advance public health responses to fatty liver disease

12. HBV DNA AND HBSAG LEVELS AT 24 WEEKS OFF-TREATMENT PREDICT CLINICAL RELAPSE AND HBSAG LOSS IN HBEAG NEGATIVE PATIENTS WHO DISCONTINUED ANTIVIRAL THERAPY

13. Patterns of Resistance-Associated Substitutions in Patients With Chronic HCV Infection Following Treatment With Direct-Acting Antivirals

19. Nicht-alkoholische Fettlebererkrankung (NAFLD) in Deutschland: Baseline-Charakteristika von Patienten aus dem Deutschen NAFLD-Register

21. Die Anlage eines transjugulären intrahepatischen portosystemischen Shunts bei Patient:innen mit dekompensierter Leberzirrhose ist mit einer signifikanten Verbesserung der Lebensqualität assoziiert

22. Global real-world evidence of sofosbuvir/velpatasvir (SOF/VEL) as a highly effective treatment in underserved patient populations because of mental health disorders, incarceration or homelessness

23. Global multi-stakeholder endorsement of the MAFLD definition

25. Bulevirtide monotherapy is safe and well tolerated in patients with chronic hepatitis D (CHD): An integrated safety analysis of 48-week data

26. Bulevirtide improves health-related quality of life measured by EQ-5D VAS in patients with chronic hepatitis delta: An exploratory analysis of a Phase 3 trial at 48 weeks

27. Efficacy of bulevirtide as monotherapy for chronic hepatitis D (CHD): Week 48 results from an integrated analysis

28. Reverse inflammaging: Long-term effects of HCV cure on biological age.

29. Virale Infektionen bei Lebertransplantierten

32. Hepatitis C: The beginning of the end—key elements for successful European and national strategies to eliminate HCV in Europe

34. A Phase 3, Randomized Trial of Bulevirtide in Chronic Hepatitis D.

37. Hepatitis

38. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts

39. Global multi-stakeholder endorsement of the MAFLD definition

40. Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

41. Global multi-stakeholder endorsement of the MAFLD definition

42. S3 Guideline: Diagnosis and Therapy of Biliary Carcinoma Short Version 2.00-June 2021, AWMF Register Number: 032-053OL

43. S3-Guideline - Diagnosis and Therapy of Biliary Carcinoma

45. Real‐world experience with the all‐oral, interferon‐free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry

49. Bulevirtide monotherapy at low and high dose in patients with chronic hepatitis delta: 24 weeks interim data of the phase 3 MYR301 study

Catalog

Books, media, physical & digital resources